Metabolic & Body Composition
GLP-1 (7-37)
Endogenous incretin that regulates postprandial glucose and satiety. The molecular basis of drugs such as semaglutide and liraglutide, which have a very short half-life in their native form.
Also known as: Glucagon-like Peptide-1 · GLP-1 receptor agonist
Specifications
| Research area | Metabolic & Body Composition | ||
|---|---|---|---|
| Half-life | ~2 minutes (native) | ||
| Molecular weight | 3298.7 Da | ||
| Amino acid residues | 31 | ||
Research areas
GlucoseDiabetesAppetiteInsulin
- Mechanism of action
- It binds to the GLP-1R receptor on pancreatic beta cells, stimulating glucose-dependent insulin secretion. It inhibits gastric emptying, reduces glucagon secretion, and acts on the hypothalamus to decrease appetite.
- Reported research ranges
- Native form with a very short half-life. It is used as a molecular reference.
- Reported adverse effects
- Mild nausea in its native form. See analogs for clinical data.
- Storage and handling
- Store at 2–8 °C.
This material is published for scientific and educational reference. It is not medical advice, not a treatment recommendation, and not an offer to sell. Compounds discussed are for research and laboratory use only.
← All compounds